Drug Discovery Research Center, Southwest Medical University, Luzhou, Sichuan, China.
Laboratory for Cardiovascular Pharmacology of the Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China.
J Thromb Haemost. 2017 Dec;15(12):2451-2460. doi: 10.1111/jth.13869. Epub 2017 Nov 8.
Essentials Vitronectin (VN) is produced by smooth muscle cells (SMCs) and promotes neointima formation. We studied the regulation of vascular VN expression by plasminogen activator inhibitor-1 (PAI-1). PAI-1 stimulates VN gene expression in SMCs by binding LDL receptor-related protein 1. Stimulation of VN gene expression may be a mechanism by which PAI-1 controls vascular remodeling.
Background Increased expression of vitronectin (VN) by smooth muscle cells (SMCs) promotes neointima formation after vascular injury, and may contribute to chronic vascular diseases, such as atherosclerosis. However, the molecular regulation of vascular VN expression is poorly defined. Given the overlapping expression profiles and functions of VN and plasminogen activator inhibitor (PAI)-1, we hypothesized that PAI-1 regulates vascular VN expression. Objectives To determine whether PAI-1 regulates VN expression in SMCs and in vivo. Methods The effects of genetic alterations in PAI-1 expression, pharmacologic PAI-1 inhibition and recombinant PAI-1 on SMC VN expression were studied, and vascular VN expression in wild-type (WT) and PAI-1-deficient mice was assessed. Results VN expression was significantly lower in PAI-1-deficient SMCs and significantly increased in PAI-1-overexpressing SMCs. PAI-1 small interfering RNA and pharmacologic PAI-1 inhibition significantly decreased SMC VN expression. Recombinant PAI-1 stimulated VN expression by binding LDL receptor-related protein-1 (LRP1), but another LRP1 ligand, α -macroglobulin, did not. As compared with WT controls, carotid artery VN expression was significantly lower in PAI-1-deficient mice and significantly higher in PAI-1-transgenic mice. In a vein graft (VG) model of intimal hyperplasia, VN expression was significantly attenuated in PAI-1-deficient VGs as compared with WT controls. The plasma VN concentration was significantly decreased in PAI-1-deficient mice versus WT controls at 4 weeks, but not at 5 days or 8 weeks, after surgery. Conclusions PAI-1 stimulates SMC VN expression by binding LRP1, and controls vascular VN expression in vivo. Autocrine regulation of vascular VN expression by PAI-1 may play important roles in vascular homeostasis and pathologic vascular remodeling.
Essentials 玻连蛋白 (VN) 由平滑肌细胞 (SMCs) 产生,促进内膜形成。我们研究了纤溶酶原激活物抑制剂-1 (PAI-1) 对血管 VN 表达的调节。PAI-1 通过 LDL 受体相关蛋白 1 结合刺激 SMCs 中 VN 基因的表达。VN 基因表达的刺激可能是 PAI-1 控制血管重塑的机制之一。
背景 血管平滑肌细胞 (SMCs) 中 vitronectin (VN) 的表达增加促进血管损伤后的内膜形成,并可能导致慢性血管疾病,如动脉粥样硬化。然而,血管 VN 表达的分子调节尚不清楚。鉴于 VN 和纤溶酶原激活物抑制剂 (PAI)-1 的重叠表达谱和功能,我们假设 PAI-1 调节血管 VN 的表达。目的 确定 PAI-1 是否调节 SMC 中和体内的 VN 表达。方法 研究了 PAI-1 表达的遗传改变、药物抑制 PAI-1 和重组 PAI-1 对 SMC VN 表达的影响,并评估了野生型 (WT) 和 PAI-1 缺陷型小鼠的血管 VN 表达。结果 PAI-1 缺陷型 SMCs 中的 VN 表达明显降低,而 PAI-1 过表达型 SMCs 中的 VN 表达明显增加。PAI-1 小干扰 RNA 和药物抑制 PAI-1 显著降低 SMC VN 表达。重组 PAI-1 通过结合 LDL 受体相关蛋白-1 (LRP1) 刺激 VN 表达,但另一种 LRP1 配体 α -巨球蛋白则没有。与 WT 对照组相比,PAI-1 缺陷型小鼠的颈动脉 VN 表达明显降低,而 PAI-1 转基因小鼠的 VN 表达明显升高。在静脉移植物 (VG) 内膜增生模型中,与 WT 对照组相比,PAI-1 缺陷型 VG 中的 VN 表达明显减弱。与 WT 对照组相比,PAI-1 缺陷型小鼠的血浆 VN 浓度在手术后 4 周时明显降低,但在 5 天或 8 周时则没有。结论 PAI-1 通过结合 LRP1 刺激 SMC VN 表达,并在体内控制血管 VN 表达。PAI-1 对血管 VN 表达的自分泌调节可能在血管稳态和病理性血管重塑中发挥重要作用。